Biogen’s QALSODY received positive opinion from CHMP

Biogen announced the Committee for Medicinal Products for Human Use , CHMP, of the European Medicines Agency, EMA, adopted a positive opinion recommending a marketing authorization under exceptional circumstances for QALSODY for the treatment of adults with amyotrophic lateral sclerosis, ALS, associated with a mutation in the superoxide dismutase 1, SOD1, gene. If authorized by the European Commission, EC, QALSODY will be the first treatment approved in the European Union to target a genetic cause of ALS, also known as motor neuron disease.